UA74588C2 - Method for locating compounds suitable for treatment and/or prophylaxis of obesity (variants) and use of such compounds for production of anti-obesity drugs (variants) - Google Patents
Method for locating compounds suitable for treatment and/or prophylaxis of obesity (variants) and use of such compounds for production of anti-obesity drugs (variants) Download PDFInfo
- Publication number
- UA74588C2 UA74588C2 UA2003021453A UA2003021453A UA74588C2 UA 74588 C2 UA74588 C2 UA 74588C2 UA 2003021453 A UA2003021453 A UA 2003021453A UA 2003021453 A UA2003021453 A UA 2003021453A UA 74588 C2 UA74588 C2 UA 74588C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compounds
- obesity
- treatment
- differs
- mammals
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 76
- 238000000034 method Methods 0.000 title claims abstract description 68
- 208000008589 Obesity Diseases 0.000 title claims abstract description 38
- 235000020824 obesity Nutrition 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims abstract description 33
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 claims abstract description 27
- 102000003846 Carbonic anhydrases Human genes 0.000 claims description 41
- 108090000209 Carbonic anhydrases Proteins 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 31
- 230000002265 prevention Effects 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 24
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims description 20
- 241000282412 Homo Species 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 210000001789 adipocyte Anatomy 0.000 claims description 9
- 230000001773 anti-convulsant effect Effects 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000002207 metabolite Substances 0.000 claims description 7
- 241000283984 Rodentia Species 0.000 claims description 6
- 238000010352 biotechnological method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 210000003494 hepatocyte Anatomy 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 20
- 229960004394 topiramate Drugs 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000004132 lipogenesis Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013367 dietary fats Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000611750 Coregonus kiyi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 108050004689 Inhibitor of carbonic anhydrases Proteins 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100133904 Mus musculus Nrk gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 1
- 229950005098 ethoxzolamide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003165 hydrotropic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10035227A DE10035227A1 (de) | 2000-07-20 | 2000-07-20 | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
| PCT/EP2001/008051 WO2002007821A1 (de) | 2000-07-20 | 2001-07-12 | Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA74588C2 true UA74588C2 (en) | 2006-01-16 |
Family
ID=7649538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003021453A UA74588C2 (en) | 2000-07-20 | 2001-12-07 | Method for locating compounds suitable for treatment and/or prophylaxis of obesity (variants) and use of such compounds for production of anti-obesity drugs (variants) |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1307262B1 (pl) |
| JP (1) | JP2004504053A (pl) |
| KR (1) | KR100818827B1 (pl) |
| CN (1) | CN1443085B (pl) |
| AR (1) | AR028730A1 (pl) |
| AT (1) | ATE278441T1 (pl) |
| AU (2) | AU2001277534B9 (pl) |
| BR (1) | BR0112547A (pl) |
| CA (1) | CA2416647A1 (pl) |
| CZ (1) | CZ2003156A3 (pl) |
| DE (2) | DE10035227A1 (pl) |
| DZ (1) | DZ3393A1 (pl) |
| ES (1) | ES2230346T3 (pl) |
| HK (1) | HK1057499A1 (pl) |
| HU (1) | HUP0302309A3 (pl) |
| IL (2) | IL153971A0 (pl) |
| MX (1) | MXPA02012907A (pl) |
| NO (1) | NO20030233L (pl) |
| NZ (1) | NZ523960A (pl) |
| PL (1) | PL201165B1 (pl) |
| PT (1) | PT1307262E (pl) |
| RU (1) | RU2268721C2 (pl) |
| SK (1) | SK287607B6 (pl) |
| TR (1) | TR200402670T4 (pl) |
| TW (1) | TWI274157B (pl) |
| UA (1) | UA74588C2 (pl) |
| WO (1) | WO2002007821A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005110413A2 (en) | 2004-05-19 | 2005-11-24 | Solvay Pharmaceuticals Gmbh | Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| AU2006249577A1 (en) | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
| AR057570A1 (es) | 2005-11-14 | 2007-12-05 | Solvay Pharm Gmbh | Derivados de n-sulfamoil-n'-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o |
| AR058389A1 (es) * | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| JP2009537635A (ja) | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
| US8455432B2 (en) | 2007-01-25 | 2013-06-04 | Verva Pharmaceuticals Ltd. | Insulin sensitisers and methods of treatment |
| CA2729056A1 (en) | 2008-06-23 | 2010-01-21 | Janssen Pharmaceutica Nv | Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| KR20150023405A (ko) * | 2012-05-24 | 2015-03-05 | 베바 파마슈티칼스 엘티디 | 간 기능 개선 방법 |
| CN106770611B (zh) * | 2016-12-22 | 2019-01-29 | 广西师范大学 | 一种用于细胞原位检测小分子化合物进入线粒体的方法 |
| RU2771430C1 (ru) * | 2021-09-21 | 2022-05-04 | Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) | Способ количественного определения антиконвульсантов в плазме крови больных эпилепсией |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4552897A (en) * | 1983-02-01 | 1985-11-12 | American Cyanamid Company | Salts of 1-(aminodihalophenyl)-2-aminoethanols and antilipogenic compositions prepared therefrom |
| US6288095B1 (en) * | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| DE69305091T2 (de) * | 1992-10-29 | 1997-03-13 | Genentech Inc | Methode zur behandlung oder verhütung von fettleibigkeit |
| AU693478B2 (en) * | 1994-11-10 | 1998-07-02 | Metabolic Pharmaceuticals Limited | Treatment of obesity |
| AP1285A (en) * | 1996-06-28 | 2004-06-24 | Ortho Mcneil Pharm Inc | Anticonvulsant sulfamate derivatives useful in treating obesity. |
| US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
-
2000
- 2000-07-20 DE DE10035227A patent/DE10035227A1/de not_active Withdrawn
-
2001
- 2001-06-15 AR ARP010102883A patent/AR028730A1/es unknown
- 2001-07-12 WO PCT/EP2001/008051 patent/WO2002007821A1/de active IP Right Grant
- 2001-07-12 PL PL363518A patent/PL201165B1/pl not_active IP Right Cessation
- 2001-07-12 IL IL15397101A patent/IL153971A0/xx unknown
- 2001-07-12 TR TR2004/02670T patent/TR200402670T4/xx unknown
- 2001-07-12 AU AU2001277534A patent/AU2001277534B9/en not_active Ceased
- 2001-07-12 JP JP2002513551A patent/JP2004504053A/ja active Pending
- 2001-07-12 AU AU7753401A patent/AU7753401A/xx active Pending
- 2001-07-12 SK SK61-2003A patent/SK287607B6/sk not_active IP Right Cessation
- 2001-07-12 CA CA002416647A patent/CA2416647A1/en not_active Abandoned
- 2001-07-12 DZ DZ013393A patent/DZ3393A1/xx active
- 2001-07-12 KR KR1020037000620A patent/KR100818827B1/ko not_active IP Right Cessation
- 2001-07-12 ES ES01955345T patent/ES2230346T3/es not_active Expired - Lifetime
- 2001-07-12 EP EP01955345A patent/EP1307262B1/de not_active Expired - Lifetime
- 2001-07-12 CN CN018129730A patent/CN1443085B/zh not_active Expired - Fee Related
- 2001-07-12 CZ CZ2003156A patent/CZ2003156A3/cs unknown
- 2001-07-12 AT AT01955345T patent/ATE278441T1/de active
- 2001-07-12 BR BR0112547-8A patent/BR0112547A/pt not_active Application Discontinuation
- 2001-07-12 HU HU0302309A patent/HUP0302309A3/hu unknown
- 2001-07-12 PT PT01955345T patent/PT1307262E/pt unknown
- 2001-07-12 DE DE50104023T patent/DE50104023D1/de not_active Expired - Lifetime
- 2001-07-12 MX MXPA02012907A patent/MXPA02012907A/es active IP Right Grant
- 2001-07-12 RU RU2003104803/14A patent/RU2268721C2/ru not_active IP Right Cessation
- 2001-07-12 NZ NZ52396001A patent/NZ523960A/xx not_active IP Right Cessation
- 2001-07-16 TW TW090117382A patent/TWI274157B/zh not_active IP Right Cessation
- 2001-12-07 UA UA2003021453A patent/UA74588C2/uk unknown
-
2003
- 2003-01-15 IL IL153971A patent/IL153971A/en not_active IP Right Cessation
- 2003-01-17 NO NO20030233A patent/NO20030233L/no unknown
-
2004
- 2004-01-15 HK HK04100307.4A patent/HK1057499A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA74588C2 (en) | Method for locating compounds suitable for treatment and/or prophylaxis of obesity (variants) and use of such compounds for production of anti-obesity drugs (variants) | |
| Dwyer et al. | Plant and human neutrophil oxidative burst complexes contain immunologically related proteins | |
| Rigutto et al. | Activation of dual oxidases Duox1 and Duox2 | |
| Ohshima et al. | Increased nitrosamine and nitrate biosynthesis mediated by nitric oxide synthase induced in hamsters infected with liver fluke (Opisthorchis viverrini) | |
| US6946243B2 (en) | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity | |
| JP2008510723A (ja) | 血管新生の治療法 | |
| Carter et al. | Decreased urinary output of tyramine and its metabolites in depression | |
| Verdy et al. | Quantitative assessment of lactate and progerin production in normal human cutaneous cells during normal ageing: Effect of an Alaria esculenta extract | |
| EP0729356A1 (en) | Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases | |
| WO2000057871A2 (en) | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof | |
| AU2004317897B2 (en) | Activation of hypoxia-inducible gene expression | |
| Matsunaga et al. | Reactive oxygen species as a risk factor in verotoxin-1-exposed rats | |
| Van Geldre et al. | L-citrulline recycling by argininosuccinate synthetase and lyase in rat gastric fundus | |
| Julémont et al. | Recent developments in 5lipoxygenase inhibitors | |
| Neves et al. | Nitric oxide-mediated immune complex-induced prostaglandin E2 production by peripheral blood mononuclear cells of humans infected with Schistosoma mansoni | |
| CN118161490B (zh) | 一种去泛素化酶抑制剂在制备预防或者治疗炎症药物中的应用 | |
| KR100442322B1 (ko) | 이소시트릭산 탈수소화효소 활성 저해제를 유효성분으로포함하는 비만, 고지혈증 또는 지방간 예방 또는 치료제 | |
| JP7422388B2 (ja) | アクアポリン３の発現亢進能を有する短鎖脂肪酸 | |
| CN115837019A (zh) | α-酮戊二酸、含有α-酮戊二酸的米发酵液在制备5α-还原酶抑制剂中的用途 | |
| CN116139159A (zh) | 一种prdx6蛋白的抑制剂在制备改善氧化应激损伤的药物中的应用 | |
| Edgett | Regulation of SIRT1, sirt3, PGC-1α, and LRP130 in response to energetic stress in human skeletal muscle | |
| Gong et al. | Articles in PresS. J Appl Physiol (September 15, 2005). doi: 10.1152/japplphysiol. 00873.2005 | |
| Klopocka et al. | Systemic and Metabolic Changes Observed in Alcohol Dependent Male Patients After Alcohol Withdrawal | |
| Hu | Characterization of human pyruvate dehydrogenase kinase isoform 2 (PDHK2) | |
| Eschenröder et al. | ENHANCED EXPRESSION OF CARNITINE PALMITOYL TRANSFERASE-Ia (CPT-Icx) IN RAT MESANGIAL CELLS BY EXOGENOUS SECRETED PHOSPHOLIPASE А2-ПА |